Page 81 - CIBER-BBN2016-ENG

Most relevant scientific articles
• Sepúlveda-Crespo D., Vacas-Córdoba E., Márquez-Miranda V., Araya-Duran I., Gómez R., Mata F.J.D.L. et al. Effect of Several HIV Antigens Simultaneously Loaded with G2-NN16 Carbosilane Dendrimer in the Cell Uptake and Functionality of Human Dendritic Cells. Bioconjugate Chemistry. 2016;27(12):2844- 2849.
• Perise-Barrios A.J., Fuentes-Paniagua E., Sánchez-Nieves J., Serramía M.J., Alonso E., Reguera R.M. et al. Improved Efficiency of Ibuprofen by Cationic Carbosilane Dendritic Conjugates. Molecular Pharmaceutics. 2016;13(10):3427-3438.
• Cena-Díez R., Vacas-Córdoba E., García-Broncano P., de la Mata F.J., Gómez R., Maly M. et al. Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: Mechanism of antiviral action. International Journal of Nanomedicine. 2016;11:2147-2162.
• Sepúlveda-Crespo D., Cena-Díez R., Jiménez J.L., Ángeles Munoz-Fernández M.. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides as Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections. Medicinal Research Reviews. 2016.
• Cena-Díez R., García-Broncano P., de la Mata F.J., Gómez R., Munoz-Fernández M.A. Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen. International Journal of Nanomedicine. 2016;11:2443-2450.
Highlights
Along the year 2016 we have been recognized for our innovative concepts involving the use of dendrimers as versatile nano-vectors for the treatment of HIV-1 and HSV-2 in National and International Congress.
We work on two concepts: nanotechnology and dendrimers with various characteristics for use in gene therapy, drug carriers and in infectious diseases. We would like to highlight the use as i) therapeutics nanovaccines against the HIV-1 infection. The greatest challenge in designed anti-miRNA therapy for HIV-1 is delivering the miRNAs to relevant cells in vitro and in vivo. One potential delivery approach that may be amenable to large-scale production is the use of dendrimers that efficiently deliver miRNAs, particularly
if they can be modified with targeting ligands promoting preferential uptake into the relevant cells and in h-BLT mouse model as a consequence comprising the HIV-1 reservoir; ii) to prevent sexually transmitted viruses. The technology developed this year has shown a great efficacy of dendrimers as prophylaxis as microbicides against HIV-1, and HIV-1/HSV-2 co-infection. Our dendrimer, G2-S16 is a promising candidate for future microbicide first-in-human clinical trial in the field for prevention of vaginal HIV-1-infection in women. We have elaborated a preclinical Phase I, First-in-Human, randomized, double-blind, placebo- controlled study to assess the Safety, Tolerability and Acceptability of the 3% G2-S16 gel as vaginal microbicide in healthy sexually active women. Information from this study help us decide whether this
gel is safe to move onto the next phase. Design: Phase I, randomized, double blind, placebo-controlled, parallel-group study; primary objective: To assess the safety of 7 consecutive daily vaginal applications of 3% G2-S16 gel in healthy, sexually active, HIV-uninfected women; Outcome Measures: Safety, Tolerability and Acceptability. Asphalion has considered that this phase I clinical study is appropriate to evaluate the safety and tolerability of G2-S16 as a FIH trial.
BBN
Research Groups 81